Opioid Use Disorder Increases 30-Day Readmission Risk in Inflammatory Bowel Disease Hospitalizations: a Nationwide Matched Analysis.
The opioid epidemic has become increasingly concerning, with the ever-increasing prescribing of opioid medications in recent years, especially in IBD patients with chronic pain. We aimed to isolate the effect of Opioid Use Disorder (OUD) on 30-day readmission risk after an IBD-related hospitalization. We retrospectively extracted IBD-related adult hospitalizations and 30-day, any-cause, readmissions from the National Readmissions Database (period 2010-2014). OUD and 30-day readmission trends were calculated. Conventional and exact-matched (EM) logistic regression and time-to-event analyses were conducted among patients who did not undergo surgery during the index hospitalization, to estimate the effect of OUD on 30-day readmission risk. 487,728 cases were identified. 6,633 (1.4%) had documented OUD. 308,845 patients (63.3%) had Crohn's. Mean age was 44.8±0.1 years, 54.3% women. Overall, 30-day readmission rate was 19.4% (n=94,546), higher in OUD patients (32.6% vs. 19.2%; p<0.001). OUD cases have been increasing (1.1% to 1.7%; p-trend<0.001), while 30-day readmission rates were stable (p-trend=0.191). In time-to-event exact-matched analysis, OUD patients were 47% more likely (hazard ratio 1.47;95%CI:1.28-1.69;p<0.001) to be readmitted, with on average being re-admitted 32% earlier (time ratio 0.68;95%CI:0.59-0.78;p<0.001). OUD prevalence has been increasing in hospitalized IBD patients from 2010-2014. On average, one in five patients will be readmitted within 30 days, with up to one in three among the OUD subgroup. OUD is significantly associated with increased 30-day readmission risk in IBD patients and further measures relating to closer post-discharge outpatient follow-up and pain management should be considered to minimize 30-day readmission risk.